Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma - Takeaways - MDSpire

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

  • By

  • Rajshekhar Chakraborty

  • Heloise Cheruvalath

  • Anannya Patwari

  • Aniko Szabo

  • Carolina Schinke

  • Binod Dhakal

  • Suzanne Lentzsch

  • Anita D’Souza

  • Ghulam Rehman Mohyuddin

  • Kelley Julian

  • Shonali Midha

  • Patrick Costello

  • Martin Kaiser

  • Melissa Ng Liet Hing

  • Simon J. Harrison

  • Edward R. Scheffer Cliff

  • Meera Mohan

  • August 12, 2024

  • 0 min

Share

  • 1

    Bispecific antibodies targeting BCMA and GPRC5D show response rates of 57–71% in relapsed/refractory multiple myeloma patients.

  • 2

    Fixed-duration dosing of bispecific antibodies may reduce T-cell exhaustion and improve patient outcomes compared to continuous exposure.

  • 3

    In a study of 23 patients who discontinued bispecific antibody treatment, 82.6% remained alive and progression-free at a median follow-up of 15.5 months.

  • 4

    The most common reasons for discontinuation of bispecific antibody therapy included infections, second malignancies, and neutropenia.

  • 5

    Patients with sustained remission after bispecific antibody discontinuation maintained or improved their response depth at the latest follow-up.

Original Source(s)

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

  • by Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan

  • August 12, 2024

Related Content

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation